234 related articles for article (PubMed ID: 34571073)
1. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control.
Nguyen PV; Allard-Vannier E; Chourpa I; Hervé-Aubert K
Int J Pharm; 2021 Aug; 605():120795. PubMed ID: 34119579
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.
Akbarzadeh Khiavi M; Safary A; Barar J; Ajoolabady A; Somi MH; Omidi Y
Cell Mol Life Sci; 2020 Mar; 77(6):997-1019. PubMed ID: 31563999
[TBL] [Abstract][Full Text] [Related]
4. Ligand-based active targeting strategies for cancer theranostics.
Bandyopadhyay A; Das T; Nandy S; Sahib S; Preetam S; Gopalakrishnan AV; Dey A
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3417-3441. PubMed ID: 37466702
[TBL] [Abstract][Full Text] [Related]
5. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
6. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
8. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.
Gener P; Gouveia LP; Sabat GR; de Sousa Rafael DF; Fort NB; Arranja A; Fernández Y; Prieto RM; Ortega JS; Arango D; Abasolo I; Videira M; Schwartz S
Nanomedicine; 2015 Nov; 11(8):1883-92. PubMed ID: 26238079
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
12. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
13. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
14. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
16. Innovative Diagnostic Peptide-Based Technologies for Cancer Diagnosis: Focus on EGFR-Targeting Peptides.
Ahmadi M; Ahmadyousefi Y; Salimi Z; Mirzaei R; Najafi R; Amirheidari B; Rahbarizadeh F; Kheshti J; Safari A; Soleimani M
ChemMedChem; 2023 Feb; 18(3):e202200506. PubMed ID: 36357328
[TBL] [Abstract][Full Text] [Related]
17. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
[TBL] [Abstract][Full Text] [Related]
18. CD44 targeted PLGA nanomedicines for cancer chemotherapy.
Saneja A; Arora D; Kumar R; Dubey RD; Panda AK; Gupta PN
Eur J Pharm Sci; 2018 Aug; 121():47-58. PubMed ID: 29777858
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer.
Omidi Y; Mobasher M; Castejon AM; Mahmoudi M
J Drug Target; 2022 Aug; 30(7):687-708. PubMed ID: 35321601
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy.
Habban Akhter M; Sateesh Madhav N; Ahmad J
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1188-1198. PubMed ID: 29991287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
